ScripBristol Myers Squibb’s Opdivo Qvantig, the new subcutaneous version of its PD-1 inhibitor Opdivo (nivolumab), will be available starting in early January with a list price that is at parity with the o
Pink SheetUS Food and Drug Administration approval decisions for endocrine and metabolic disease therapies will crescendo through the rest of 2024, and could briefly make more noise than the perpetually dominan
ScripHalozyme Therapeutics is pulling back from its attempt to acquire Evotec after the German service provider appeared uninterested in the offer, though Halozyme remains convinced that the two firms are
ScripShares in Germany’s Evotec are on the rise thanks to an unsolicited takeover bid from Halozyme Therapeutics but the size of the offer – around €2.00bn ($2.12bn) – suggests that any potential deal is s